跳至主要内容
临床试验/NCT01470339
NCT01470339已完成不适用

Improvement the Anti-migraine Treatment Efficacy by Tailoring the Drug to Individual's Pain Modulation Profile

Rambam Health Care Campus1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2011年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
200
试验地点
1
主要终点
Distinguish between two endogenous pain modulation mechanisms

研究概览

简要总结

  • To delineate brain mechanisms that subserve endogenous analgesic (EA) in the healthy state.
  • To identify alterations in mechanisms supporting EA in chronic pain (migraine) and their therapeutic relevance.

详细描述

The proposed research will use psychophysics and multiparametric MRI to (i) delineate the brain mechanisms that subserve and regulate endogenous analgesia (EA)in the healthy state and (ii) to identify alterations in mechanisms supporting EA in chronic pain and their therapeutic relevance. In both healthy subjects and chronic pain patients, EA will be probed using the DNIC (diffuse noxious inhibitory controls) and offset analgesia paradigms. Functional MRI will examine activation of brainstem mechanisms important in EA, while both functional and structural connectivity analyses will assess the regulation of these brainstem mechanisms by cerebral cortical regions involved in attention and affect. One pathological painful condition, migraine, will be examined since it allows changes in EA associated with chronic pain to be investigated between episodes of pain. Finally, EA and EA associated structural and functional parameters will be used to predict the efficacy of one compound, amitriptyline, to treat migraine in individual patients. Taken together, the proposed research will provide substantial insights into basic mechanisms supporting and regulating EA and can provide a foundation for mechanism-based individualized choice of therapy that may benefit all chronic pain patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • healthy females
  • migaine females
  • ages 18-50
  • for migraineurs: >4 attacks/month

排除标准

  • any migraine preventive treatment received during last 3 months or prior treatment with amytriptiline
  • other chronic pain conditions
  • psychiatric, other neurological diseases, language barrier or cognitive dysfunction
  • Patients and controls will be asked to withdraw from any pain-relieving medications for 24 hours before the testing. The tests will be performed interictally atleast 2 days after the last attack.

研究组 & 干预措施

placebo

Placebo Comparator

migraine patients to receive placebo treatment

干预措施: duloxetine (Drug)

duloxetine

Active Comparator

migraine patients to receive duloxetine

干预措施: duloxetine (Drug)

结局指标

主要结局

Distinguish between two endogenous pain modulation mechanisms

时间窗: 2 year

次要结局

  • To charcterize functional and structural neuroanatomical correlates of pain modulation profile and it's relevance for predicting the duloxetine efficacy in migraine(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

d_yarnitsky

Professor, Head on Neurology Department

Rambam Health Care Campus

研究点 (1)

Loading locations...

相似试验